Experiment: Testing newly chemically modified crRNA and tracrRNA in mouse Hepa 1-6 cells
PI: Erik J Sontheimer, PhD
Description: Chemically modified crRNA and tracrRNA were delivered by electroporation to mouse Hepa 1-6 cells. Editing activity was determined by Sanger sequencing
Editing Assay:
Calculated editing efficiency by PCR amplification and sanger sequencing analysis.
Parent Project: Enhancing CRISPR Gene Editing in Somatic Tissues by Chemical Modification of Guides and Donors
-
Other experiments in this project: 10
- Testing newly chemically modified crRNA and tracrRNA in mTmG mouse embryonic fibroblasts
- Delivery of unmodified, phosphorothioate (PS)-stabilized crRNA with chemically modified, PS-stabilized tracrRNA using the S10 shuttle peptide to activate the mTmG reporter in mouse brain
- Delivery of unmodified, phosphorothioate (PS)-stabilized crRNA with chemically modified, extended PS-stabilized tracrRNA to activate the mTmG reporter in mouse brain
- Delivery of chemically modified, phosphorothioate (PS)-stabilized crRNA with chemically modified, PS-stabilized tracrRNA to activate the mTmG reporter in mouse brain
- Delivery of chemically modified, phosphorothioate (PS)-stabilized crRNA with chemically modified, extended PS-stabilized tracrRNA to activate the mTmG reporter in mouse brain
- Testing preparation for independent validation at The Jackson Laboratory Small Animal Testing Center
- Testing newly chemically modified crRNA and tracrRNA to activate the TLR reporter in human cells
- Testing newly chemically modified crRNA and tracrRNA to activate the TLR1 reporter in human cells
- Testing newly chemically modified crRNA and tracrRNA in mouse Neuro 2A cells
- Delivery of RNP containing chemically modified crRNA C20 with chemically modified tracrRNA T2-PS to determine the RNP distribution in TLR-MCV mouse brain
Download: Submitted files
Select experimental variable to highlight records on the chart:
Note: Hover over the bars to view additional information
Results |
| Editing Efficiency | ||||||||
|---|---|---|---|---|---|---|---|---|
| Condition | Sex | Editor | Model | Target Locus | Guide | Dosage | % of Lesion | Image |
| STS96 (PCSK9a) (20 pmol RNP) | Female | SpyCas9-3xNLS | Hepa1-6 | Pcsk9 | STS96 (PCSK9a; Sp_t2:Sp_c20_PCSK9a) | 20 pmol RNP | ||
| STS134 (PCSK9b) (5 pmol RNP) | Female | SpyCas9-3xNLS | Hepa1-6 | Pcsk9 | STS134 (PCSK9b; Sp_t2:Sp_c20_PCSK9b) | 5 pmol RNP | ||
| STS134 (PCSK9b) (20 pmol RNP) | Female | SpyCas9-3xNLS | Hepa1-6 | Pcsk9 | STS134 (PCSK9b; Sp_t2:Sp_c20_PCSK9b) | 20 pmol RNP | ||
| STS135 (PCSK9c) (20 pmol RNP) | Female | SpyCas9-3xNLS | Hepa1-6 | Pcsk9 | STS135 (PCSK9c; Sp_t2:Sp_c20_PCSK9c) | 20 pmol RNP | ||
| STS204 (DNMT1) (5 pmol RNP) | Female | SpyCas9-3xNLS | Hepa1-6 | Dnmt1 | STS204 (DNMT1; Sp_t41:Sp_c20_Dnmt1) | 5 pmol RNP | ||
| STS205 (BACE1) (5 pmol RNP) | Female | SpyCas9-3xNLS | Hepa1-6 | Bace1 | STS205 (BACE1; Sp_t41:Sp_c20_Bace1) | 5 pmol RNP | ||
× Close Overview
